Jiang He
Has grant
Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Open
Targeting tumor-specific epitope for imaging and therapy for mesothelioma
Open Date: 2025-01-01
Close Date: 2029-12-31
Grant: Close
Novel radioimmunoconjugates for targeted alpha-particle therapy of metastatic prostatic cancer
Open Date: 2018-06-01
Close Date: 2023-05-31
Grant: Close
Novel systemic delivery of siRNA for atherosclerosis
Open Date: 2014-02-01
Close Date: 2017-01-31
Grant: Close
Targeted liposomal radiotherapy of malignant mesothelioma
Open Date: 2008-08-11
Close Date: 2013-05-31
Grant: Close
Institutional Research Grant
Open Date: 2008-01-01
Close Date: 2011-12-31
Articles (38)
Purpose: CD46 is highly expressed across multiple cancer types, including prostate cancer and multiple myeloma. We have developed CD46-targeting antibody–drug conjugate (ADC) and actinium-225 (225Ac)–based α particle therapy agents that demonstrated a tumor-selective therapeutic effect. We hypothesized that a treatment strategy targeting CD46 using simultaneous ADC and radioimmunotherapy methods would have synergistic therapeutic efficacy with acceptable toxicity. Experimental Design: Two CD46-targeted combination treatment strategies were evaluated: (i) co-administration of the ADC (YS5-MMAE) and 225Ac-labeled antibody ([225Ac]Macropa-PEG4-YS5) and (ii) a dual-payload radioconjugate ([225Ac]Macropa-PEG4-YS5-MMAE; R-ADC). The in vitro synergy was studied using cell viability, DNA damage, and apoptosis assays. In vivo studies were performed for biodistribution, toxicity, and therapeutic evaluation in subcutaneous, disseminated, and patient-derived xenograft models of prostate cancer and multiple myeloma. Results: Combination therapy induced synergistic G2–M arrest, increased γ-H2AX foci, and enhanced cell death compared with monotherapies. R-ADC and co-administration strategies resulted in improved tumor control and survival benefit. Conclusions: By integrating orthogonal microtubule inhibition and high–linear energy transfer α irradiation on a single CD46 scaffold, potent, well-tolerated tumor control was achieved across diverse models. The dual-payload construct’s compatibility with CD46 immuno-PET for real-time dosimetry further supports progression to early-phase clinical trials in prostate cancer and multiple myeloma.
Year:
2026
Purpose: Metastatic castration-resistant prostate cancer has limited treatment options and a poor prognosis. Recently, prostate-specific membrane antigen (PSMA)-targeted alpha-particle therapy agents using actinium-225 (225Ac) have shown promising results in prostate cancer treatment, but a significant fraction of patients with advanced mCRPC demonstrate loss of PSMA expression. We have previously reported that PSMA-null and PSMA-positive tumors can be detected and treated effectively with CD46-targeted radiopharmaceuticals. This study evaluates the CD46-targeting PET imaging agent [89Zr]DFO-YS5, and the radioimmunotherapy agent [225Ac]Macropa-PEG4-YS5, in disseminated prostate cancer tumors. Experimental Design: Microtumor lesions, primarily observed in the liver, kidneys, and lungs, were successfully detected with [89Zr]DFO-YS5 PET imaging. We used disseminated 22Rv1 tumors for biodistribution studies, dosimetry assessments, and therapeutic efficacy evaluations of [225Ac]Macropa-PEG4-YS5. Results: Quantitative digital alpha-particle autoradiography revealed high radiation dose deposition from [225Ac]Macropa-PEG4-YS5 in microtumors compared with surrounding liver tissues, although in larger lesions (>1 mm diameter), the dose distribution was heterogeneous. Early treatment of smaller disseminated tumors with a uniform radiation dose was more effective in ablating tumors and promoting survival. In late-stage lesions of large size, heterogeneous dose deposition limited therapeutic efficacy, requiring higher administered activity to achieve a complete response. Conclusions: Our findings highlight that [225Ac]Macropa-PEG4-YS5 holds the potential for clinical translation for metastatic prostate cancer and reinforces the value of microdosimetry in understanding the efficacy of and resistance to targeted alpha therapy. See related commentary by Patel et al., p. 2847
Year:
2025
Overweight and obese individuals show lower mortality rates or better prognoses than those of normal weight in a variety of diseases, a phenomenon called the “obesity paradox”. An inverse association of adiposity with atherosclerosis has been observed in both humans and mice. To dissect phenotypic and genetic connections between the traits, 154 female and 145 male F2 mice were generated from an intercross between BALB/cJ and LP/J apolipoprotein E-deficient mice and fed a Western diet for 12 weeks. Atherosclerotic lesion size in the aortic root, body weight, plasma lipids, and glucose were measured, and genotyping was performed on miniMUGA SNP arrays. Quantitative trait locus (QTL) analyses on all F2 mice with sex as a covariate revealed four significant QTLs on chromosomes (Chr) 3, 6, 13, and 15 for atherosclerosis and three significant QTLs on Chr2, 7, and 15 for body weight. Chr15 QTL for atherosclerosis overlapped with one for body weight near 36 Mb. After adjusting for variation in body weight, Chr15 atherosclerosis QTL was downgraded from significant to suggestive linkage. Body weight was inversely correlated with atherosclerotic lesion sizes and accounted for more variance than a single other risk factor for atherosclerosis among F2 mice. Analysis of public data collected from two backcross cohorts revealed strong correlations between body weight and fat mass in adult mice (r ≥ 0.93; p ≤ 1.6 × 10−136). Thus, the obesity paradox in atherosclerosis is partially attributable to shared genetic components that have an opposite effect on adiposity and atherosclerosis.
Year:
2025
Purpose Plectin is traditionally an intracellular cytoskeletal protein that maintains cell structure and stability. However, we and others have identified its surface-localized form in cancer (CSP), where it influences cell adhesion, migration, immune response, and tumor signaling. CSP-positive tumors (pancreatic, lung, ovarian, and breast cancers) contribute to over 3 million annual deaths, highlighting its clinical relevance. This phase 0 study aimed to evaluate PTP-01’s ability to target CSP in pancreatic tumors, despite their dense desmoplastic stroma, and to estimate CSP density and tumor vascularity. Methods Pancreatic cancer patients ( n = 3) received an intravenous injection of 100 µg PTP-01 labeled with 370 MBq 111 In one day before resection. Whole-body planar scintigraphy and SPECT imaging were performed at multiple time points. Resected tumors and adjacent tissues were collected 28 h post-injection. Blood and urine samples were obtained for pharmacokinetic analysis. Tissue biodistribution was assessed using whole-body SPECT scans. Results PTP-01 injection caused no reported adverse events. Uptake was primarily observed in the kidneys, liver, and bladder, with some tumor uptake. CSP density in tumors was estimated at 10⁶ molecules per cell. The elimination half-life (T₁/₂) ranged from 5 to 22 h across patients. Conclusion PTP-01 imaging of pancreatic tumors revealed the ability of a targeted agent to bind to CSP. Further, CSP density in tumors was estimated to be on par with other surface molecules such as Her2 with effective targeted therapies. This study suggests that CSP is a highly expressed, accessible molecule for the development of targeted therapies such as antibodies or antibody–drug conjugates.
Year:
2025
Figure S4: Gamma energy spectra of the tumor, blood, kidneys, and bone showing the intensities of the 213Bi and 221Fr peaks. As compared to the equilibrium gamma energy spectra of [225Ac]DOTA-YS5, increased intensity of the 213Bi was observed in kidney samples.
Year:
2025
Figure S11: Antitumor activity of [225Ac]DOTA-YS5 in subcutaneous DU145 tumors in nude mice. Tumor volume, survival analysis, and weight measurements after the injections of [225Ac]DOTA-YS5 in DU145 xenografts (n=6).
Year:
2025
Figure S10: Tumor volumes, overall survival, and body weights for the saline and fractionated dose (0.125 µCi x 3) injections in 22Rv1 xenografts. Results show delayed tumor growth and improved survival without the significant toxicity from fractionated dose treatment (n=10).
Year:
2025
Figure S9: Histology evaluation of the healthy tissues for long-term (117 days) toxicity analysis. Hematoxylin and Eosin (H&E) staining of spleen, liver, lungs, heart, and bone samples show no toxicity at 0.25 µCi or 0.5 µCi doses of [225Ac]DOTA-YS5. Scale bar: 20 µm
Year:
2025
Figure S7: Analysis of CD46 expression in correlation with of the [225Ac]DOTA-YS5 uptake and DNA damage. Digital autographs, H &E staining, and immunofluorescence (Rabbit Isotype control+DAPI, CD46 & phospho-γ-H2Ax) of the tumor tissues injected with [225Ac]DOTA-YS5 for day 1, day 2, day 4, and day 7.
Year:
2025
Figure S8: Acute toxicity study of the [225Ac]DOTA-YS5 in nude mice (n=5). A The body weights of mice injected with [225Ac]DOTA-YS5 showed no significant change in treatment groups over the 15 days study period. B&C: Liver and kidney function tests (B) and blood parameters (C) show no significant changes for saline vs. treated groups indicating the short-term safety of [225Ac]DOTA-YS5.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Collaborators (18)
Nancy Y. Greenland
-
Arun Wiita
Associate Professor
University of California, San Francisco
Li Zhang
Professor
UCSF
Emily Chan
Stanford University
Henry VanBrocklin
Professor/ Director of Radiopharmaceutical Research
University of California, San Francisco
weibin shi
Professor
University of Virginia
David M. Wilson
University of California
Renuka Sriram
University of California
Emily Egusa
University of California, San Francisco
Anil Parsram Bidkar
Assistant Professional Researcher
University of California, San Francisco
Jonathan Chou
Assistant Professor
University of California, San Francisco
sinan wang
Assistant Professor
University of California, San Francisco
Robert R. Flavell
University of California
Y. Seo
University of California, San Francisco
Rahul Aggarwal
University of California
Megha Basak
University of California, San Francisco
Scott C. Kogan
University of California, San Francisco
kondapa Naidu Bobba
Assistant professor
University of Tennessee
Make your next move.
Prepare your application
Review drafts before you send them.